The Rosen Law Firm has issued an update regarding a class action lawsuit filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR). The firm represents investors who allegedly suffered losses due to purportedly misleading statements made by Capricor.
The lawsuit claims that Capricor misled investors about the efficacy and safety data related to deramiocel, its lead cell therapy candidate for treating cardiomyopathy linked to Duchenne muscular dystrophy (DMD). Specifically, the complaint alleges that Capricor made overly optimistic statements regarding the drug’s prospects for approval by the U.S. Food and Drug Administration (FDA).
According to the firm, these positive statements were made while Capricor allegedly withheld or misrepresented data from the Phase 2 HOPE-2 trial. This omission, the lawsuit argues, artificially inflated the price of CAPR securities. When the true information emerged, the firm contends that investors experienced significant financial losses.
Rosen Law Firm is investigating these allegations. The firm encourages investors who purchased CAPR stock during the class period, defined as October 9, 2024, to July 10, 2025, to contact them. Investors who wish to serve as lead plaintiff in the class action must file their motions with the court by September 15, 2025.
Becoming the lead plaintiff involves representing the interests of other class members in guiding the litigation. However, participation is not mandatory to potentially receive compensation. Those choosing not to actively participate can remain as absent class members.
Rosen Law Firm clarified that its representation is on a contingency fee basis; therefore, investors incur no upfront costs or expenses. The firm highlights its experience in shareholder rights litigation, stating its commitment to recovering losses for shareholders and holding companies accountable for alleged wrongdoing.
The Rosen Law Firm, with offices in New York City, emphasizes its history of recovering over $1 billion for shareholders. The firm encourages interested parties to contact Attorney Phillip Kim or submit an inquiry through their website for more information. This information is for informational purposes only and should not be considered legal advice.
Related
